Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ.

08:00 EDT 3rd May 2019 | BioPortfolio

Summary of "Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ."

Local macrophage proliferation is linked to enhanced atherosclerosis progression. Our previous study found that troglitazone, a thiazolidinedione (TZD), suppressed oxidized low-density lipoprotein (Ox-LDL)-induced macrophage proliferation. However, its effects and mechanisms are unclear. Therefore, we investigated the effects of pioglitazone, another TZD, on macrophage proliferation.


Journal Details

This article was published in the following journal.

Name: Atherosclerosis
ISSN: 1879-1484
Pages: 30-39


DeepDyve research library

PubMed Articles [12009 Associated PubMed Articles listed on BioPortfolio]

Apolipoprotein M suppresses the phenotypes of IgA nephropathy in hyper-IgA mice.

Because the association between sphingosine 1-phosphate (S1P)/apolipoprotein M (ApoM) and chronic kidney diseases has not been established, we investigated the involvement of S1P/ApoM in the phenotype...

BMI1 Deficiency Results in Female Infertility by Activating p16/p19 Signaling and Increasing Oxidative Stress.

The polycomb repressor B lymphoma Mo-MLV insertion region 1 (BMI1) is a core composition of polycomb repressive complex 1 (PRC1) and contributes to diverse fundamental cellular processes including cel...

Protocatechuic Acid Attenuates Atherosclerosis by Inhibiting M1 and Promoting M2 Macrophage Polarization.

Macrophage polarization has a vital impact on the progression of atherosclerosis (AS). Protocatechuic acid (PCA), a flavonol, displays notable atheroprotective effects, but its mechanisms have not bee...

Macrophage-specific HIF-1α deletion suppresses the development of liver tumors in high fat diet-fed obese and diabetic mice.

Chronic inflammation of the liver is often observed with obesity or type 2 diabetes. In these pathological conditions, the immunological cells, such as macrophages, play important roles in the develop...

Elimination of adrenocortical apolipoprotein E production does not impact glucocorticoid output in wild-type mice.

Apolipoprotein E (APOE) deficient mice exhibit unexplained hypercorticosteronemia. Given that APOE is also produced locally within the adrenals, we evaluated the effect of adrenal-specific APOE defici...

Clinical Trials [1740 Associated Clinical Trials listed on BioPortfolio]

Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

Pulmonary alveolar proteinosis (PAP) is a syndrome of surfactant accumulation, respiratory failure, and innate immune deficiency for which therapy remains limited to whole lung lavage (WLL...

Pioglitazone in Psoriasis- A Clinical and Molecular Study.

The study will assess the effectiveness of Pioglitazone on cellular and clinical levels in terms of improvement of both skin and systemic manifestations of psoriasis. The investigators as...

Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.

The purpose of this study is to asses changes in glycosylated hemoglobin, fasting blood lipids and genetic polymorphism's in peroxisomal proliferator activated receptors--gamma receptor af...

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.

Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes

SPECIFIC AIMS 1. To determine whether pioglitazone will reduce levels of ADMA in patients with diabetes. 2. To determine whether nitric oxide products (NOx) are increased with piogli...

Medical and Biotech [MESH] Definitions

A minor apolipoprotein that associates with HIGH-DENSITY LIPOPROTEINS (HDL), VERY-LOW-DENSITY LIPOPROTEINS (VLDL), and CHYLOMICRONS. It regulates levels of plasma TRIGLYCERIDES by activating APOLIPOPROTEIN C-II LIPOPROTEIN LIPASE and inhibiting hepatic VLDL triglyceride hydrolysis.

Factors secreted by stimulated lymphocytes that prime macrophages to become nonspecifically cytotoxic to tumors. They also modulate the expression of macrophage cell surface Ia antigens. One MAF is INTERFERON-GAMMA. Other factors antigenically distinct from IFN-gamma have also been identified.

A mononuclear phagocyte colony-stimulating factor (M-CSF) synthesized by mesenchymal cells. The compound stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series. M-CSF is a disulfide-bonded glycoprotein dimer with a MW of 70 kDa. It binds to a specific high affinity receptor (RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR).

A major and the second most common isoform of apolipoprotein E. In humans, Apo E4 differs from APOLIPOPROTEIN E3 at only one residue 112 (cysteine is replaced by arginine), and exhibits a lower resistance to denaturation and greater propensity to form folded intermediates. Apo E4 is a risk factor for ALZHEIMER DISEASE and CARDIOVASCULAR DISEASES.

A 34-kDa glycosylated protein. A major and most common isoform of apolipoprotein E. Therefore, it is also known as apolipoprotein E (ApoE). In human, Apo E3 is a 299-amino acid protein with a cysteine at the 112 and an arginine at the 158 position. It is involved with the transport of TRIGLYCERIDES; PHOSPHOLIPIDS; CHOLESTEROL; and CHOLESTERYL ESTERS in and out of the cells.

Quick Search


DeepDyve research library

Searches Linking to this Article